

AMENDMENTS TO THE CLAIMS

The claims in this listing will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 (Currently Amended): Sustained release tablet containing ~~indapamide, characterized in that the tablet contains indapamide in the amount 1.5 to 2.5 % of the total mass of the tablet of indapamide, lactose monohydrate in the amount 30 to 80 % of the total mass of the tablet of lactose monohydrate, cepevidon in the amount of 2 to 10 % of the total mass of the tablet of copovidon, hypromellose in the amount of 20 to 65 % of the total mass of the tablet of hypromellose, and lubricants in the amount of 0.1 to 5 % of the total mass of the tablet of lubricant.~~

Claim 2 (Currently Amended): ~~Tablet~~ The tablet according to claim 1, ~~characterized in that as the lubricants it contains wherein said lubricant comprises at least one of magnesium stearate or/and and anhydrous colloidal silica.~~

Claim 3 (Currently Amended): ~~Tablet~~ The tablet according to claim 1, ~~characterized in that wherein the hypromellose has a viscosity is from 1.000 1,000 to 20.000 20,000 cP.~~

Claim 4 (Currently Amended): Process of manufacturing sustained release tablet containing indapamide, characterized in that comprising mixing indapamide ~~is mixed~~ with lactose monohydrate and copovidone and then moisturizing the mixture ~~is moisturised by~~ with purified water and its performing granulation ~~is performed~~ after which the granulate is dried, cooled, mixed with hypromellose and lubricants lubricant and compressed in tableting machine.

Claim 5 (New): The process according to claim 4, wherein said lubricant comprises at least one of magnesium stearate and anhydrous colloidal silica.

Claim 6 (New): The process according to claim 4, wherein the hypromellose has a viscosity ~~is~~ from 1,000 to 20,000 cP.